Exelixis (EXEL) Stock Forecast & Price Target

Compare

3,146 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EXEL Analyst Ratings

Moderate Buy

6 Buy

7 Hold

1 Sell

Based on 14 analysts giving stock ratings to

Exelixis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EXEL Stock 12 Month Forecast

Average Price Target

$46.73

▲(13.31% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $46.73 with a high forecast of $60.00 and a low forecast of $35.00. The average price target represents a 13.31% change from the last price of $41.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","61":"$61","40.75":"$40.8","47.5":"$47.5","54.25":"$54.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,40.75,47.5,54.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.03,42.48923076923077,43.94846153846154,45.40769230769231,46.86692307692308,48.326153846153844,49.785384615384615,51.244615384615386,52.70384615384616,54.16307692307692,55.62230769230769,57.08153846153846,58.54076923076923,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.03,41.46846153846154,41.90692307692308,42.34538461538462,42.783846153846156,43.222307692307695,43.66076923076923,44.099230769230765,44.5376923076923,44.97615384615384,45.41461538461538,45.85307692307692,46.29153846153846,{"y":46.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.03,40.566153846153846,40.10230769230769,39.63846153846154,39.174615384615386,38.71076923076923,38.246923076923075,37.783076923076926,37.31923076923077,36.855384615384615,36.39153846153846,35.92769230769231,35.463846153846156,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.81,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.03,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$46.73

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sean Laaman

Morgan Stanley

$49

Hold

18.82%

Upside

Reiterated

03/08/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)

Jay Olson

Oppenheimer

$36

Hold

-12.71%

Downside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

03/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Mineralys Therapeutics, Inc. (NASDAQ: MLYS), Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT)

Leonid Timashev

RBC Capital

$46→$43

Hold

4.27%

Upside

Reiterated

03/01/26

RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL)

Stephen Willey

Stifel Nicolaus

―

Hold

―

Reiterated

03/01/26

Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility

Robert Burns

H.C. Wainwright

$52→$54

Buy

30.94%

Upside

Reiterated

02/12/26

Exelixis: Solid Financial Beat and Advancing Oncology Pipeline Drive Upgraded Earnings Outlook and $54 Price Target

Unknown Analyst

Stephens

Not Ranked

Stephens

$60

Buy

45.49%

Upside

Reiterated

02/11/26

Exelixis (EXEL) Receives a Buy from Stephens

Yaron Werber

TD Cowen

$51

Buy

23.67%

Upside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and OrganiGram Holdings (NASDAQ: OGI)

Derek Archila

Wells Fargo

$30→$35

Hold

-15.13%

Downside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (NASDAQ: EXEL), Edwards Lifesciences (NYSE: EW) and Zimmer Biomet Holdings (NYSE: ZBH)

Michael Schmidt

Guggenheim

―

Hold

―

Reiterated

02/10/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Exelixis (NASDAQ: EXEL), Incyte (NASDAQ: INCY) and Compass Therapeutics (NASDAQ: CMPX)

Jason Gerberry

Bank of America Securities

$41

Sell

-0.58%

Downside

Reiterated

02/10/26

Bank of America Securities Keeps Their Sell Rating on Exelixis (EXEL)

Paul Choi

Goldman Sachs

$50

Buy

21.24%

Upside

Reiterated

02/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Quest Diagnostics (NYSE: DGX), Exelixis (NASDAQ: EXEL) and Gilead Sciences (NASDAQ: GILD)

Etzer Darout

Barclays

$41→$44

Hold

6.69%

Upside

Reiterated

02/04/26

Barclays Sticks to Its Hold Rating for Exelixis (EXEL)

Asthika Goonewardene

Truist Financial

$49→$51

Buy

23.67%

Upside

Reiterated

01/14/26

Truist Financial Sticks to Their Buy Rating for Exelixis (EXEL)

Akash Tewari

Jefferies

$46

Buy

11.54%

Upside

Reiterated

12/11/25

Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sean Laaman

Morgan Stanley

$49

Hold

18.82%

Upside

Reiterated

03/08/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)

Jay Olson

Oppenheimer

$36

Hold

-12.71%

Downside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

03/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Mineralys Therapeutics, Inc. (NASDAQ: MLYS), Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT)

Leonid Timashev

RBC Capital

$46→$43

Hold

4.27%

Upside

Reiterated

03/01/26

RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL)

Stephen Willey

Stifel Nicolaus

―

Hold

―

Reiterated

03/01/26

Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility

Robert Burns

H.C. Wainwright

$52→$54

Buy

30.94%

Upside

Reiterated

02/12/26

Exelixis: Solid Financial Beat and Advancing Oncology Pipeline Drive Upgraded Earnings Outlook and $54 Price Target

Unknown Analyst

Stephens

Not Ranked

Stephens

$60

Buy

45.49%

Upside

Reiterated

02/11/26

Exelixis (EXEL) Receives a Buy from Stephens

Yaron Werber

TD Cowen

$51

Buy

23.67%

Upside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and OrganiGram Holdings (NASDAQ: OGI)

Derek Archila

Wells Fargo

$30→$35

Hold

-15.13%

Downside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (NASDAQ: EXEL), Edwards Lifesciences (NYSE: EW) and Zimmer Biomet Holdings (NYSE: ZBH)

Michael Schmidt

Guggenheim

―

Hold

―

Reiterated

02/10/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Exelixis (NASDAQ: EXEL), Incyte (NASDAQ: INCY) and Compass Therapeutics (NASDAQ: CMPX)

Jason Gerberry

Bank of America Securities

$41

Sell

-0.58%

Downside

Reiterated

02/10/26

Bank of America Securities Keeps Their Sell Rating on Exelixis (EXEL)

Paul Choi

Goldman Sachs

$50

Buy

21.24%

Upside

Reiterated

02/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Quest Diagnostics (NYSE: DGX), Exelixis (NASDAQ: EXEL) and Gilead Sciences (NASDAQ: GILD)

Etzer Darout

Barclays

$41→$44

Hold

6.69%

Upside

Reiterated

02/04/26

Barclays Sticks to Its Hold Rating for Exelixis (EXEL)

Asthika Goonewardene

Truist Financial

$49→$51

Buy

23.67%

Upside

Reiterated

01/14/26

Truist Financial Sticks to Their Buy Rating for Exelixis (EXEL)

Akash Tewari

Jefferies

$46

Buy

11.54%

Upside

Reiterated

12/11/25

Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

3 Months

xxx

Success Rate

13/17 ratings generated profit

Average Return

+11.70%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +11.70% per trade.

1 Year

Jason GerberryBank of America Securities

Success Rate

17/17 ratings generated profit

Average Return

+32.09%

a rating ―

Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.09% per trade.

2 Years

xxx

Success Rate

16/17 ratings generated profit

Average Return

+50.58%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +50.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXEL Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EXEL has received 11 Buy Ratings, 20 Hold Ratings, and 2 Sell Ratings. EXEL average Analyst price target in the past 3 months is 46.73.

Each month's total comprises the sum of three months' worth of ratings.

EXEL Financial Forecast

EXEL Earnings Forecast

Next quarter’s earnings estimate for EXEL is $0.76 with a range of $0.65 to $0.84. The previous quarter’s EPS was $0.94. EXEL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year EXEL has Performed in-line its overall industry.

EXEL Sales Forecast

Next quarter’s sales forecast for EXEL is $608.80M with a range of $578.00M to $630.00M. The previous quarter’s sales results were $598.66M. EXEL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year EXEL has Performed in-line its overall industry.

EXEL Stock Forecast FAQ

What is EXEL’s average 12-month price target, according to analysts?

Based on analyst ratings, Exelixis’s 12-month average price target is 46.73.

What is EXEL’s upside potential, based on the analysts’ average price target?

Exelixis has 13.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EXEL a Buy, Sell or Hold?

Exelixis has a consensus rating of Moderate Buy which is based on 6 buy ratings, 7 hold ratings and 1 sell ratings.

What is Exelixis’s price target?

The average price target for Exelixis is 46.73. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $35.00. The average price target represents 13.31% Increase from the current price of $41.24.

What do analysts say about Exelixis?

Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of EXEL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Exelixis (EXEL) Stock Forecast & Price Target

EXEL Analyst Ratings

EXEL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Exelixis

EXEL Analyst Recommendation Trends

EXEL Financial Forecast

EXEL Earnings Forecast

EXEL Sales Forecast

EXEL Stock Forecast FAQ

Detailed List of Analyst Forecasts